{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:16Z","timestamp":1789419796639,"version":"build-2803163510"},"reference-count":75,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To review the characteristics, efficacy, safety, pharmacoeconomics, and place in therapy of upadacitinib, a Janus kinase (JAK) inhibitor, in the treatment of rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed (January 2003-May 2022) was searched using upadacitinib and ABT-494.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Human studies published in peer-reviewed publications in English were the primary sources for efficacy and safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In randomized, double-blind, controlled clinical studies, upadacitinib demonstrated statistically significant improvement in RA symptoms as monotherapy and in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) when compared with csDMARD monotherapy or to adalimumab or abatacept in combination with csDMARD therapy in patients with RA. American College of Rheumatology 20% response rates were 68% to 79% for upadacitinib monotherapy and 64% to 84% for upadacitinib plus csDMARD therapy, compared with 28% to 59% for csDMARD-only therapy and 63% to 74% for biologic DMARD (bDMARD) plus csDMARD therapy. Long-term extension studies demonstrated similar findings. Upadacitinib had similar rates of serious infections, herpes zoster, major cardiovascular events, and venous thromboembolic events as other JAK inhibitors. Upadacitinib was similar in cost to tofacitinib and twice as high as baricitinib based on current estimated costs to patients, but actual costs may vary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Upadacitinib is an alternative therapy to other JAK inhibitors and bDMARDs in patients with moderate to severe RA who have had an inadequate response to a tumor necrosis factor inhibitor alone or in combination with a csDMARD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Upadacitinib is an effective JAK inhibitor for use in RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221113092","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:25:53Z","timestamp":1659493553000},"page":"450-462","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-9016","authenticated-orcid":false,"given":"Eric G.","family":"Boyce","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Rogan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"C. Lui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655."},{"key":"e_1_3_2_4_2","unstructured":"Rinvoq (upadacitinib) [package insert]. North Chicago IL: AbbVie Inc.; 2021. Accessed March 25 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211675s002s005lbl.pdf."},{"key":"e_1_3_2_5_2","unstructured":"Drug Approval Package: RINVOQ. US Food & Drug Administration. Accessed March 25 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000TOC.cfm."},{"key":"e_1_3_2_6_2","unstructured":"Xeljanz (tofacitinib) [package insert]. New York NY: Pfizer Laboratories Div. of Pfizer Inc.; 2021. Accessed June 23 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/203214s028 208246s013 213082s003lbl.pdf."},{"key":"e_1_3_2_7_2","unstructured":"Olumiant (baricitinib) [package insert]. Indianapolis IN: Eli Lilly and Company; 2021. Accessed March 25 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207924s004lbl.pdf."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20621."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780281203."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1513."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1350."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00739-3."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31325-4."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1543"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.462."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0378-y."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41384."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13329."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa084."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1847776."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02387-6."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39808."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39801."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2037-1."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2059-8."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa770."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X21999564."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.01.039."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00796-1."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01303-3."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13616."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-022-01165-w."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-019-0601-3"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.804."},{"key":"e_1_3_2_46_2","unstructured":"US Food & Drug Administration. Janus Kinase (JAK) inhibitors: Drug Safety Communication\u2014FDA Requires Warnings about Increased Risk of Serious Heart-related Events Cancer Blood Clots and Death. US Food & Drug Administration; 2021. Accessed March 25 2022. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214846"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41580."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez087."},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001749."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-021-00153-5."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216653."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0178."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00822-x."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1774550."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1496."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002110."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix419."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0419-y."},{"key":"e_1_3_2_61_2","unstructured":"Rinvoq Prices Coupons and Patient Assistance Programs. Drugs.com. Accessed March 25 2022. https:\/\/www.drugs.com\/price-guide\/rinvoq."},{"key":"e_1_3_2_62_2","unstructured":"Rinvoq: Cost Questions. AbbVie Inc. Accessed March 25 2022. https:\/\/www.rinvoq.com\/cost."},{"key":"e_1_3_2_63_2","unstructured":"Xeljanz Prices Coupons and Patient Assistance Programs. Drugs.com. Accessed March 25 2022. https:\/\/www.drugs.com\/price-guide\/xeljanz."},{"key":"e_1_3_2_64_2","unstructured":"Xeljanz XR Prices Coupons and Patient Assistance Programs. Drugs.com. Accessed March 25 2022. https:\/\/www.drugs.com\/price-guide\/xeljanz-xr."},{"key":"e_1_3_2_65_2","unstructured":"Xeljanz Pricing. Pfizer Inc. Accessed March 25 2022. https:\/\/www.pfizerrxpricing.com\/xeljanz."},{"key":"e_1_3_2_66_2","unstructured":"Olumiant Prices Coupons and Patient Assistance Programs. Drugs.com. Accessed March 25 2022. https:\/\/www.drugs.com\/price-guide\/olumiant."},{"key":"e_1_3_2_67_2","unstructured":"How much should I expect to pay for Olumiant\u00ae? Eli Lilly and Company. Accessed March 25 2022. https:\/\/www.lillypricinginfo.com\/olumiant?utm_id=go_cmp-9593811538_adg-98603319333_ad-424383810190_kwd-422993310120_dev-c_ext-_prd-_mca-_sig-EAIaIQobChMI78WIio3G9AIVpmxvBB3e4QQoEAAYASAAEgLoF_D_BwE&utm_source=google&gclid=EAIaIQobChMI78WIio3G9AIVpmxvBB3e4QQoEAAYASAAEgLoF_D_BwE."},{"key":"e_1_3_2_68_2","unstructured":"AbbVie: Patient Assistance Program. AbbVie Inc. Accessed March 25 2022. https:\/\/www.abbvie.com\/patients\/patient-assistance.html?utm_source=myAbbVie-Assist-URL."},{"key":"e_1_3_2_69_2","unstructured":"Xeljanz: Savings & Support. Pfizer Inc. Accessed March 25 2022. https:\/\/www.xeljanz.com\/savings-and-support."},{"key":"e_1_3_2_70_2","unstructured":"Lilly Cares\u00ae Foundation. Eli Lilly and Company. Accessed March 25 2022. https:\/\/www.lillycares.com\/."},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01930-4."},{"key":"e_1_3_2_72_2","unstructured":"CADTH Common Drug Reviews. Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie). Canadian Agency for Drugs and Technologies in Health; 2020. Accessed March 25 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558494\/pdf\/Bookshelf_NBK558494.pdf."},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0757-2."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit816."},{"key":"e_1_3_2_75_2","unstructured":"COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic Musculoskeletal Diseases. ACR COVID-19 Vaccine Clinical Guidance Task Force. American College of Rheumatology. Version 5. February 2 2022. Accessed May 12 2022. https:\/\/www.rheumatology.org\/Portals\/0\/Files\/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf."},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221113092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221113092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221113092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:59Z","timestamp":1777375019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221113092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/10600280221113092"],"URL":"https:\/\/doi.org\/10.1177\/10600280221113092","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}